Therapeutics News and Research

RSS

New drug mimics low-oxygen treatment for Leigh Syndrome

For the average person, living at high altitude-where oxygen is sparser than at sea level-can have health benefits ranging from lower rates of heart disease to increased endurance.

18 Feb 2025

Study reveals surge in sports betting and gambling addiction help seeking

A new study, published in JAMA Internal Medicine and led by researchers from the University of California San Diego Qualcomm Institute and School of Medicine, reveals a dramatic increase in sports betting and gambling addiction help-seeking since the landmark Murphy v. NCAA Supreme Court decision in 2018 paved the way for states to legalize sports betting.

17 Feb 2025

AI tool speeds up patient screening for heart failure trials

Artificial intelligence (AI) can rapidly screen patients for clinical trial enrollment, according to a new study published in JAMA and led by Mass General Brigham researchers.

17 Feb 2025

Breakthrough technology enables mRNA delivery across the blood-brain barrier

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.

17 Feb 2025

A step toward precision medicine: New drug targets for heart failure

Researchers identify several promising drug targets for heart failure and its clinical subtypes.

14 Feb 2025

Study reveals brain circuit linked to human creativity

A new study led by researchers at Mass General Brigham suggests that different brain regions activated by creative tasks are part of one common brain circuit.

13 Feb 2025

Identifying key brain circuit opens doors for new psychosis treatments

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, disorganized thinking and detachment from reality.

13 Feb 2025

Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the launch of ClinFAST™, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.

13 Feb 2025

Study finds varying cardiovascular risks associated with different hormonal contraceptives

Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws on prescription records to give more precise estimates for different products than previous studies.

13 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

UCLA study reveals key role of mismatch repair genes in Huntington’s disease

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease and triggering downstream pathologies and motor impairment, shedding light on disease mechanisms and potential new ways to develop therapies.

11 Feb 2025

Duke engineers develop synthetic approach to boost bacterial protein synthesis

Biomedical engineers at Duke University have demonstrated a new synthetic approach that turbocharges bacteria into producing more of a specific protein, even proteins that would normally destroy them, such as antibiotics.

11 Feb 2025

Insilico Medicine announces preclinical drug discovery benchmarks from 2021 to 2024

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 developmental candidate nominations achieved by its platform from 2021 to 2024.

11 Feb 2025

Lung signals trigger blood clot formation in cancer patients

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health. Clots are the second-leading cause of death among cancer patients with advanced disease or aggressive tumors.

11 Feb 2025

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

11 Feb 2025

GUK1 enzyme plays crucial role in lung cancer metabolism and growth

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

10 Feb 2025

Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).

10 Feb 2025

Modifying biomaterials may lead to more effective cancer therapies

Modifying the physical characteristics of microscopic biomaterials to interact seamlessly with the body's tissues could unlock safer and more effective cancer treatments, according to Virginia Tech researchers at the Fralin Biomedical Research Institute at VTC.

7 Feb 2025

Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.

7 Feb 2025

Pancreatic cancer immune landscape reveals opportunities for personalized therapies

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies.

7 Feb 2025